Neurocrine Biosciences Inc. reports biopharmaceutical developments across neurological, psychiatric, endocrine and immunological disorders. Recurring updates include commercial and clinical information for INGREZZA for tardive dyskinesia and chorea associated with Huntington's disease, CRENESSITY for classic congenital adrenal hyperplasia, and approved therapies for endometriosis and uterine fibroids.
Company news also covers CAHtalyst clinical data, peer-reviewed publications on glucocorticoid dosing and the Tardive Dyskinesia Impact Scale, pipeline programs such as NBIP-'2118, financial results, healthcare conference participation, and governance or capital-structure matters tied to Neurocrine's public-company reporting.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Neurocrine Biosciences (NASDAQ: NBIX) has announced a conference call and webcast scheduled for May 3, 2023, to discuss its Q1 2023 financial results. The press release will be available at 4:30 a.m. PT / 7:30 a.m. ET, followed by the conference call at 5:00 a.m. PT / 8:00 a.m. ET. Interested parties can join via phone using the domestic number 800-895-3361 or the international number 785-424-1062, with Conference ID NBIX. A webcast of the call will be accessible on the company’s website, and a replay will be available for one month afterward.
Neurocrine Biosciences (NASDAQ: NBIX) will present at the Stifel 2023 CNS Days on Tuesday, March 28, 2023, at 12:30 p.m. Eastern Time. Eiry Roberts, Chief Medical Officer, and Kyle Gano, Chief Business Development and Strategy Officer, will represent the company.
The live presentation will be webcasted and can be accessed on Neurocrine's website under the Investors section. A replay of the event will be available about one hour after the presentation and archived for one month.
Neurocrine Biosciences, Inc. (NASDAQ: NBIX) announced the publication of data from the RE-KINECT study, the largest real-world analysis of patients with possible tardive dyskinesia (TD). The study showed that patients aware of their involuntary movements reported significant negative impacts on their health and social functioning. An important finding was the disconnect between clinician-rated TD severity and patient perceptions. The study assessed 1,148 patients and highlighted the need for clinicians to evaluate both the presence of TD and its effects on daily life for better treatment plans. This research underlines the necessity for comprehensive assessments of the quality of life in TD patients.